ECSP12012249A - Derivados del acido 1-amino-2-ciclopropiletilboronico - Google Patents

Derivados del acido 1-amino-2-ciclopropiletilboronico

Info

Publication number
ECSP12012249A
ECSP12012249A ECSP12012249A ECSP12012249A EC SP12012249 A ECSP12012249 A EC SP12012249A EC SP12012249 A ECSP12012249 A EC SP12012249A EC SP12012249 A ECSP12012249 A EC SP12012249A
Authority
EC
Ecuador
Prior art keywords
ciclopropiletilboronico
derivatives
amino
acid
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Jing Li
Paul Robert Fleming
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012249(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of ECSP12012249A publication Critical patent/ECSP12012249A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención proporciona nuevos compuestos útiles como inhibidores de proteasoma. La invención también proporciona composiciones farmacéuticas que comprenden los compuestos de la invención y métodos para usar las composiciones en el tratamiento de diferentes enfermedades
ECSP12012249 2010-03-31 2012-10-11 Derivados del acido 1-amino-2-ciclopropiletilboronico ECSP12012249A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31946410P 2010-03-31 2010-03-31

Publications (1)

Publication Number Publication Date
ECSP12012249A true ECSP12012249A (es) 2012-11-30

Family

ID=44710349

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012249 ECSP12012249A (es) 2010-03-31 2012-10-11 Derivados del acido 1-amino-2-ciclopropiletilboronico

Country Status (26)

Country Link
US (3) US8513218B2 (es)
EP (1) EP2552216B1 (es)
JP (1) JP5933523B2 (es)
KR (1) KR20130036228A (es)
CN (3) CN107266485A (es)
AR (1) AR080863A1 (es)
AU (1) AU2011235227B2 (es)
CA (1) CA2794334C (es)
CL (1) CL2012002733A1 (es)
CO (1) CO6630162A2 (es)
CR (1) CR20120529A (es)
DO (1) DOP2012000257A (es)
EA (1) EA029521B1 (es)
EC (1) ECSP12012249A (es)
MA (1) MA34169B1 (es)
MX (1) MX2012011298A (es)
NZ (1) NZ602622A (es)
PE (1) PE20130383A1 (es)
PH (1) PH12012501943A1 (es)
RU (1) RU2012146101A (es)
SG (1) SG184222A1 (es)
TN (1) TN2012000465A1 (es)
UA (1) UA110612C2 (es)
UY (1) UY33314A (es)
WO (1) WO2011123502A1 (es)
ZA (2) ZA201207406B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8716322B2 (en) 2005-11-09 2014-05-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
JP5734656B2 (ja) 2007-10-04 2015-06-17 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤結晶及びアミノ酸ケトエポキシドの調製
DK2730581T3 (en) 2008-06-17 2016-08-15 Millennium Pharm Inc Boronate Ester Compounds and Pharmaceutical Compositions thereof.
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EA024364B1 (ru) 2008-10-21 2016-09-30 Оникс Терапьютикс, Инк. Способ лечения множественной миеломы
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
CA2791651C (en) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
AU2011235227B2 (en) 2010-03-31 2016-09-08 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
KR102205755B1 (ko) 2010-08-10 2021-01-22 렘펙스 파머수티클스 인코퍼레이티드 고리형 보론산 에스터 유도체의 결정 형태
WO2013071163A2 (en) 2011-11-11 2013-05-16 Millennium Pharamaceuticals, Inc. Biomarkers of response to proteasome inhibitors
EP2776043B1 (en) 2011-11-11 2018-02-21 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
JP6129203B2 (ja) * 2011-12-22 2017-05-17 アレス トレーディング ソシエテ アノニム α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤
US20160008382A1 (en) 2012-01-24 2016-01-14 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
CN103570806B (zh) * 2012-07-26 2020-04-07 圣特莱国际公司 多肽环氧酮化合物
JP2016509594A (ja) 2013-01-04 2016-03-31 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN105705149A (zh) 2013-10-03 2016-06-22 米伦纽姆医药公司 用于预防或治疗系统性红斑狼疮和/或狼疮性肾炎的方法
US9988421B2 (en) 2014-01-10 2018-06-05 Cornell University Dipeptides as inhibitors of human immunoproteasomes
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
FI3604316T3 (fi) 2014-05-05 2024-02-29 Melinta Therapeutics Inc Boronaattisuolojen synteesi
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2015264272A1 (en) 2014-05-20 2016-11-24 Millennium Pharmaceuticals, Inc. Boron-containing proteasome inhibitors for use after primary cancer therapy
EA201692301A1 (ru) 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
WO2016022955A1 (en) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
EP3193904B1 (en) 2014-08-18 2025-10-01 Cornell University Dipeptidomimetics as inhibitors of human immunoproteasomes
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3362754B1 (en) 2015-10-15 2021-12-22 Cornell University Proteasome inhibitors and uses thereof
UA124464C2 (uk) 2016-06-30 2021-09-22 Кьюпекс Біофарма, Інк. Похідні боронової кислоти та їх терапевтичні застосування
ES3036483T3 (en) 2017-02-28 2025-09-19 Mayo Found Medical Education & Res Combinations for use in the treatment of cancer
EP3694605A4 (en) 2017-10-11 2021-10-27 Cornell University PEPTIDOMIMETIC PROTEASOME INHIBITORS
EP3694864B1 (en) 2017-10-11 2025-03-05 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
WO2019204419A1 (en) 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
AU2021266715A1 (en) 2020-05-05 2022-11-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203706A (en) 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5159060A (en) 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
ES2098484T3 (es) 1992-08-14 1997-05-01 Procter & Gamble Detergentes liquidos que contienen un acido alfa-amino-boronico.
US5492900A (en) 1993-09-10 1996-02-20 Neutron Technology Corporation Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA)
US6060462A (en) 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
EP0979096B1 (en) 1997-02-15 2003-05-14 Millennium Pharmaceuticals, Inc. Treatment of infarcts through inhibition of nf-kappab
JP2001517631A (ja) 1997-09-25 2001-10-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患および自己免疫疾患を治療するためのプロテアソーム阻害剤、ユビキチン経路阻害剤、またはユビキチンプロテアソーム経路を介したＮＦ−κＢの活性化に干渉する剤
US20010012854A1 (en) 1997-12-16 2001-08-09 Robert Siman Multicatalytic protease inhibitors for use as anti-tumor agents
US6169076B1 (en) 1999-03-31 2001-01-02 Glcosyn Pharmaceuticals, Inc. P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols
AU5788800A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
US7122627B2 (en) * 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
HK1048771A1 (zh) 2000-02-29 2003-04-17 Bristol-Myers Squibb Co. 低剂量艾替开韦制剂及其应用
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
DK3078667T3 (en) 2001-01-25 2019-01-07 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulation of boric acid compounds
WO2003033507A1 (en) 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Benzylmalonic acid derivatives and proteasome inhibitors contaiing the same
EP1463719A2 (en) 2002-01-08 2004-10-06 Eisai Co., Ltd Eponemycin and epoxomicin analogs and uses thereof
US20060084592A1 (en) 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
TW200418791A (en) * 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
PE20050360A1 (es) * 2003-08-14 2005-06-10 Cephalon Inc Inhibidores del proteasoma
NZ598172A (en) 2004-03-30 2013-08-30 Millennium Pharm Inc Synthesis of boronic ester and acid compounds
AU2006264305B2 (en) 2005-07-05 2012-07-05 Trustees Of Tufts College Inhibitors of fibroblast activation protein alpha
US20090304631A1 (en) 2006-01-27 2009-12-10 David Alan Campbell Hepatitis c serine protease inhibitors and uses therefor
WO2009006473A2 (en) 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
MY161991A (en) 2007-08-06 2017-05-31 Millennium Pharm Inc Proteasome inhibitors
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
DK2730581T3 (en) * 2008-06-17 2016-08-15 Millennium Pharm Inc Boronate Ester Compounds and Pharmaceutical Compositions thereof.
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
AU2011235227B2 (en) 2010-03-31 2016-09-08 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid

Also Published As

Publication number Publication date
PH12012501943A1 (en) 2017-08-23
ZA201207406B (en) 2014-01-29
CN102892291A (zh) 2013-01-23
KR20130036228A (ko) 2013-04-11
EP2552216A1 (en) 2013-02-06
UY33314A (es) 2011-10-31
US20110245203A1 (en) 2011-10-06
CN106008570A (zh) 2016-10-12
UA110612C2 (uk) 2016-01-25
RU2012146101A (ru) 2014-05-10
SG184222A1 (en) 2012-10-30
US20140011998A1 (en) 2014-01-09
AU2011235227B2 (en) 2016-09-08
EA201290980A1 (ru) 2013-03-29
MX2012011298A (es) 2012-11-06
US20140179631A1 (en) 2014-06-26
EP2552216A4 (en) 2013-07-31
US8703743B2 (en) 2014-04-22
TN2012000465A1 (en) 2014-01-30
JP5933523B2 (ja) 2016-06-08
US8513218B2 (en) 2013-08-20
WO2011123502A1 (en) 2011-10-06
AR080863A1 (es) 2012-05-16
US9023832B2 (en) 2015-05-05
CO6630162A2 (es) 2013-03-01
MA34169B1 (fr) 2013-04-03
CL2012002733A1 (es) 2013-01-25
CA2794334C (en) 2018-06-12
AU2011235227A1 (en) 2012-10-18
EA029521B1 (ru) 2018-04-30
CA2794334A1 (en) 2011-10-06
CN107266485A (zh) 2017-10-20
PE20130383A1 (es) 2013-04-24
EP2552216B1 (en) 2018-01-24
NZ602622A (en) 2015-01-30
ZA201308086B (en) 2015-03-25
DOP2012000257A (es) 2012-11-15
CR20120529A (es) 2013-01-11
JP2013523760A (ja) 2013-06-17

Similar Documents

Publication Publication Date Title
CR20120529A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
ECSP11011011A (es) Derivados de acido 1-amino-2-ciclobutiletilborónico
CR20150610A (es) Compuestos de pirimidino sustituido y derivados para combatir plagas de animales
CR20160015A (es) Compuestos de éster boronato y composiciones farmacéuticas de los mismos
ECSP10010015A (es) Inhibidores de proteasoma
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
UY35142A (es) Derivados de triazolopirazinas como inhibidores de brd4
PE20151067A1 (es) Inhibidores de autotaxina
UY32809A (es) Compuestos y composiciones como inhibidores de cinasa s y k
UY39338A (es) Derivados de piperidinona como inhibidores mdm2, composiciones farmacéuticas que los contienen y sus usos
ECSP13013074A (es) Nuevos derivados de piridina
UY35827A (es) Derivados de triazolopirazina como inhibidores de la proteína brd4
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
CR20150045A (es) Inhibidores de hepatitis c
NI201400107A (es) Compuestos de heterociclilo como inhibidores de mek
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
CR20150204A (es) Nuevos derivados de piridina
CR20140573A (es) Inhibidores del nampt
CR20140553A (es) Compuestos de fenoxietil piperidina
PE20150674A1 (es) Azaheterociclos como inhibidores de bir2 y/o bir3
AR090830A1 (es) Cocristales de metalaxil y protioconazol y procedimientos para la fabricacion y el uso de los mismos
CR20120109A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen